Corey McCann - 14 Jan 2023 Form 4 Insider Report for Pear Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Jan 2023, 16:03:45 UTC
Previous filing: 18 Feb 2022
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PEARQ	Common Stock	Options Exercise	$0	+88,000	+1.1%	$0.000000	8,245,565	14 Jan 2023	Direct
holding	PEARQ	Class A Common Stock						1,685,913	14 Jan 2023	by The Corey M. McCann Irrevocable Trust of 2021	F1, F2
holding	PEARQ	Class A Common Stock						986,517	14 Jan 2023	by The McCann Family Trust	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PEARQ	Restricted Stock Units	Options Exercise	$0	-88,000	-33%	$0.000000	178,667	14 Jan 2023	Common Stock	88,000		Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, with respect to these shares, except to the extent of his pecuniary interest therein.
F2	Shares held in The Corey M. McCann Irrevocable Trust of 2021. The trustee of The Corey M. McCann Irrevocable Trust of 2021 is Mia E. Moll.
F3	Shares held in The McCann Family Trust. The trustee of The McCann Family Trust is Concord Trust Company.
F4	Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F5	The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.